In particular, CDK4/6 inhibitors palbociclib, ribociclib and abemaciclib have shown efficacy in in vitro models of EAC [25,67] and promising results in breast cancer, non-small cell lung cancer and melanoma patients [68]. This evidence concerns the gene CDK4 and breast carcinoma.